Hayek, Salim S http://orcid.org/0000-0003-0180-349X
Koh, Kwi Hye
Grams, Morgan E
Wei, Changli
Ko, Yi-An
Li, Jing
Samelko, Beata
Lee, Hyun
Dande, Ranadheer R
Lee, Ha Won
Hahm, Eunsil http://orcid.org/0000-0002-0343-7473
Peev, Vasil
Tracy, Melissa
Tardi, Nicholas J
Gupta, Vineet http://orcid.org/0000-0001-6987-2550
Altintas, Mehmet M
Garborcauskas, Garrett
Stojanovic, Nikolina
Winkler, Cheryl A http://orcid.org/0000-0001-5552-0917
Lipkowitz, Michael S
Tin, Adrienne
Inker, Lesley A
Levey, Andrew S
Zeier, Martin
Freedman, Barry I
Kopp, Jeffrey B
Skorecki, Karl
Coresh, Josef
Quyyumi, Arshed A
Sever, Sanja
Reiser, Jochen
Article History
Received: 30 September 2016
Accepted: 1 June 2017
First Online: 26 June 2017
Competing interests
: J.R. and S.S. are cofounders of the biotech TRISAQ, and hold patents and stock in the space of proteinuric kidney disease. C.W. has a pending patent on suPAR in diabetic kidney disease. J.R., S.S., C.W. and E.H. are inventors on pending and issued patents related to anti-proteinuric therapies. They stand to gain royalties from present and future commercialization. J.C., A.S.L. and L.I. have a patent pending on GFR estimation and a collaboration agreement with Metabolon. Wake Forest University Health Sciences and B.F have filed for a patent related to <i>APOL1</i> genetic testing. B.F receives research support from Novartis Pharmaceuticals and is a consultant for Ionis and AstraZeneca Pharmaceuticals.